Payment overview · 2025
General Payments
$1,842.74
80 reported records · 17 companies
Healthcare provider profile · identity verified
Alexander Fruchter, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · MIDDLETOWN, NY · NPI 1740234160
Verified facts
What the public records show
CMS Open Payments records show Alexander Fruchter, MD received $1,842.74 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Unithroid.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Unithroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $468.10 | 25.4% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $283.69 | 15.4% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $274.74 | 14.9% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $232.72 | 12.6% | 12 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $94.15 | 5.1% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $88.99 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $80.87 | 4.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $62.18 | 3.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $55.31 | 3.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.98 | 2.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.18 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.85 | 1.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.77 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.32 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.15 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.84 | 0.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.90 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,753.75 | 79 |
| Education | $88.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $457.88 | 19 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $350.41 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $248.11 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $245.78 | 9 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $211.59 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $207.96 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.87 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $62.18 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.91 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 161 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 160 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
160 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
161 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
305 | 71 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Telmisartan | Telmisartan | 1216 | 351 |
| Amlodipine Besylate | Amlodipine Besylate | 672 | 205 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 610 | 186 |
| Metformin Hcl Er | Metformin Hcl | 594 | 194 |
| Metoprolol Succinate | Metoprolol Succinate | 558 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 445 | 124 |
| Gabapentin | Gabapentin | 439 | 144 |
| Montelukast Sodium | Montelukast Sodium | 347 | 115 |
| Torsemide | Torsemide | 344 | 119 |
| Azelastine Hcl | Azelastine Hcl | 340 | 159 |
| Eliquis | Apixaban | 305 | 71 |
| Ezetimibe | Ezetimibe | 273 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 82 |
| Alprazolam | Alprazolam | 232 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 60 |
| Ozempic | Semaglutide | 197 | 32 |
| Famotidine | Famotidine | 194 | 61 |
| Prednisone | Prednisone | 184 | 102 |
| Omeprazole | Omeprazole | 183 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 54 |
| Dexamethasone | Dexamethasone | 161 | 114 |
| Mounjaro | Tirzepatide | 161 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 160 | 48 |
| Azithromycin | Azithromycin | 159 | 97 |
| Pregabalin | Pregabalin | 151 | 45 |
| Ramipril | Ramipril | 140 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 134 | 96 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 40 |
| Jardiance | Empagliflozin | 118 | 30 |
| Metformin Hcl | Metformin Hcl | 106 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 42 |
| Nadolol | Nadolol | 102 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 100 | 27 |
| Irbesartan | Irbesartan | 91 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 90 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 28 |
| Carvedilol | Carvedilol | 87 | 25 |
| Warfarin Sodium | Warfarin Sodium | 87 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 63 |
| Sertraline Hcl | Sertraline Hcl | 85 | 25 |
| Valsartan | Valsartan | 84 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 19 |
| Rabeprazole Sodium | Rabeprazole Sodium | 79 | 35 |
| Tramadol Hcl | Tramadol Hcl | 77 | 23 |
| Finasteride | Finasteride | 76 | 23 |
| Furosemide | Furosemide | 74 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 23 |
| Spironolactone | Spironolactone | 74 | 28 |
| Simvastatin | Simvastatin | 71 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Theophylline Er | Theophylline Anhydrous | 66 | 21 |
| Topiramate | Topiramate | 65 | 15 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 64 | 22 |
| Synthroid | Levothyroxine Sodium | 63 | 20 |
| Dutasteride | Dutasteride | 61 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 20 |
| Losartan Potassium | Losartan Potassium | 59 | 15 |
| Potassium Chloride | Potassium Chloride | 59 | 19 |
| Allopurinol | Allopurinol | 57 | 18 |
| Farxiga | Dapagliflozin Propanediol | 57 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 20 |
| Modafinil | Modafinil | 55 | 14 |
| Atenolol | Atenolol | 54 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 48 |
| Trazodone Hcl | Trazodone Hcl | 48 | 25 |
| Ciclopirox | Ciclopirox Olamine | 46 | 26 |
| Diazepam | Diazepam | 46 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 43 | 11 |
| Memantine Hcl | Memantine Hcl | 41 | 13 |
| Mirtazapine | Mirtazapine | 41 | 17 |
| Cefdinir | Cefdinir | 40 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 29 |
| Baclofen | Baclofen | 39 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 14 |
| Trulicity | Dulaglutide | 37 | 12 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Unithroid | Levothyroxine Sodium | 30 | suppressed |
| Colchicine | Colchicine | 29 | 14 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Lisinopril | Lisinopril | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Minoxidil | Minoxidil | 25 | 12 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | 11 |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,842.74 · 80 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, DUPIXENT, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NUCALA, PREVNAR 20, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, TRINTELLIX, UNITHROID, Veozah, XIFAXAN, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error